solriamfetol
solriamfetol: sourced relationships with 1 company · 8 clinical trials tracked.
solriamfetol evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
How could solriamfetol → AXSM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Axsome Therapeutics, Inc. (AXSM) | Approved |
Clinical Trial Registry Records (8)
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Primary endpoint: Treatment-Emergent Adverse Events (TEAEs)
A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Primary endpoint: Time from randomization to relapse of depressive symptoms
An Open-Label and Double-Blind, Randomized Withdrawal Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Adults With Binge Eating Disorder
Primary endpoint: Time from randomization to relapse of binge eating in the RW segment
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Solriamfetol in Excessive Sleepiness Associated With Shift Work Disorder
Primary endpoint: Change from Baseline to Week 12 in the mean sleep latency time as measured by the Maintenance of Wakefulness Test (MWT).
Solriamfetol for the Treatment of Fatigue in Patients With Multiple Sclerosis and Excessive Daytime Sleepiness
Primary endpoint: Modified Fatigue Impact Scale (MFIS) Score
A Phase 3, Randomized, Double-blind, Placebo-Controlled Trial of Solriamfetol in Adults With Binge Eating Disorder (BED)
Primary endpoint: Change from Baseline to Week 12 in number of binge eating episodes
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in Adults With ADHD.
Primary endpoint: Change from Baseline to Week 6 in the AISRS total score
SUNOSI® (Solriamfetol) Pregnancy Registry: An Observational Study on the Safety of Solriamfetol Exposure in Pregnant Women and Their Offspring
Primary endpoint: Long-term Safety
Frequently asked questions
Which companies have sourced relationships with solriamfetol?
solriamfetol has dated SEC/FDA relationship records for Axsome Therapeutics, Inc..
How many clinical trials involve solriamfetol?
BioSniper tracks 8 clinical trials involving solriamfetol.